Male Breast Cancer Completed Phase 1 / 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00368875Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerTreatment